Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.

[1]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010, The Lancet. Oncology.

[2]  B. Neyns,et al.  Tolerance of adjuvant letrozole outside of clinical trials. , 2008, Breast.

[3]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. , 2008, The Lancet. Oncology.

[4]  Lang Li,et al.  Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors , 2008, Breast Cancer Research and Treatment.

[5]  H. Greenlee,et al.  Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Cuzick,et al.  Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. , 2007, Journal of the National Cancer Institute.

[7]  T. Powles,et al.  Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. , 2007, Journal of the National Cancer Institute.

[8]  J. Forbes,et al.  Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  F. Holmes,et al.  Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Cuzick,et al.  Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. , 2006, The Lancet. Oncology.

[11]  M. Kris,et al.  Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Miyagi,et al.  Historical control study of paclitaxel–carboplatin (TJ) versus conventional platinum-based chemotherapy (CAP) for epithelial ovarian cancer , 2006, International Journal of Clinical Oncology.

[13]  I. Fentiman,et al.  Hormone dependency of breast tumours developing in the Guernsey Cohort Study , 2006, Breast Cancer Research and Treatment.

[14]  H. Carlsten.  Immune responses and bone loss: the estrogen connection , 2005, Immunological reviews.

[15]  M. Reiss,et al.  Five-Year Update of an Expanded Phase II Study of Dose-Dense and -Intense Doxorubicin, Paclitaxel and Cyclophosphamide (ATC) in High-Risk Breast Cancer , 2005, Oncology.

[16]  S. Cummings,et al.  Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. , 2005, Arthritis and rheumatism.

[17]  S. Cummings,et al.  Sex Hormones, Risk Factors, and Risk of Estrogen Receptor–Positive Breast Cancer in Older Women: A Long-term Prospective Study , 2005, Cancer Epidemiology Biomarkers & Prevention.

[18]  H. Iwata,et al.  Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma , 2005, Breast cancer.

[19]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[20]  Roy E. Smith,et al.  Phase II trial of a doxorubicin/docetaxel doublet for locally advanced and metastatic breast cancer: results from national surgical adjuvant breast and bowel project trial BP-57. , 2004, Clinical breast cancer.

[21]  P. Lønning,et al.  Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study , 2003, BMJ : British Medical Journal.

[22]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer , 2003, Cancer.

[23]  R. Langer,et al.  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. , 2003, JAMA.

[24]  M. Hammar,et al.  The prevalence of symptoms possibly related to the climacteric in pre- and postmenopausal women in Linköping, Sweden. , 2003, Maturitas.

[25]  R. Langer,et al.  Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial , 2003 .

[26]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.

[27]  D. M. Lubián López,et al.  Prognosis of breast cancers detected in women receiving hormone replacement therapy. , 2001, Maturitas.

[28]  J. Cuzick,et al.  Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D Coggon,et al.  Individual risk factors for hip osteoarthritis: obesity, hip injury, and physical activity. , 1998, American journal of epidemiology.

[30]  Matthew P. Wand,et al.  Kernel Smoothing , 1995 .

[31]  F. Wolfe,et al.  The prevalence and characteristics of fibromyalgia in the general population. , 1995, Arthritis and rheumatism.

[32]  A. Silman,et al.  The prevalence of chronic widespread pain in the general population. , 1993, The Journal of rheumatology.

[33]  B. Zumoff.  Relationship of obesity to blood estrogens. , 1982, Cancer research.